Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Pandemic

- PMLiVE

COVID-19 linked to higher risk of brain fog, dementia and psychosis in new study

The study also found that adults faced an increased risk of anxiety and depression, but this subsided within two months of illness

- PMLiVE

CureVac announces start of phase 1 trial of modified COVID-19 mRNA vaccine candidate

Developed in collaboration with GSK, CV0501 is specifically designed to protect against the Omicron variant

- PMLiVE

How the WHO hepatitis strategy measures up in the field

With hepatitis cases on the rise, Dr Anthony Martinez, member of the International Hepatitis Education Program (IHEP), shares his perspective on the World Health Organization’s new strategy for hepatitis elimination...

Avalere Health

- PMLiVE

JCVI publishes advice on COVID-19 vaccines ahead of autumn booster campaign

The programme was expanded in response to the Omicron variant to include everyone aged 50 and over

- PMLiVE

WHO publishes first position paper on optimising brain health

It is estimated that one in three people will develop a neurological disorder at some point in their life, making neurological disorders the leading cause of disability

- PMLiVE

WHO releases interim statement on COVID-19 vaccination for children and adolescents

Only 25% of older populations have received a complete primary series of COVID-19 vaccines in lower income countries

- PMLiVE

The impact of COVID-19 on the fight against AMR

How the responses to the COVID-19 pandemic have affected antibiotic-resistant bacteria

- PMLiVE

Moderna’s Omicron booster receives MHRA approval

The booster dose can be used in adults aged 18 years and over to protect against contracting COVID-19

- PMLiVE

Lack of evidence for AstraZeneca’s COVID-19 vaccine says UK Department of Health

Charities have called on the government to reassess its decision, which could affect the immunocompromised

- PMLiVE

New research shows drug candidate may effectively treat antibiotic-resistant bacteria

Research published in The American Chemical Society Central Science journal has shown that Fabimycin may be effective against more than 200 antibiotic-resistant bacteria

- PMLiVE

ONS data reveals significant decrease in COVID-19 antibodies

The latest figures have prompted calls for the government to start its autumn booster vaccination campaigns as soon as possible

- PMLiVE

NHS England launches hepatitis C screening scheme to reach 2030 elimination goal

The new scheme could help diagnose up to 80,000 people who do not know they have hepatitis C

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links